MHC Class I Antigens In Malignant Cells / Najlacnejšie knihy
MHC Class I Antigens In Malignant Cells

Kód: 01428575

MHC Class I Antigens In Malignant Cells

Autor Maria Teresa Cabrera Castillo, Natalia Aptsiauri, Angel Miguel Garcia-Lora

Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described ... celý popis

70.78


Skladom u dodávateľa v malom množstve
Odosielame za 12 - 17 dní

Potrebujete viac kusov?Ak máte záujem o viac kusov, preverte, prosím, najprv dostupnosť titulu na našej zákazníckej podpore.


Pridať medzi želanie

Mohlo by sa vám tiež páčiť

Darujte túto knihu ešte dnes
  1. Objednajte knihu a vyberte Zaslať ako darček.
  2. Obratom obdržíte darovací poukaz na knihu, ktorý môžete ihneď odovzdať obdarovanému.
  3. Knihu zašleme na adresu obdarovaného, o nič sa nestaráte.

Viac informácií

Viac informácií o knihe MHC Class I Antigens In Malignant Cells

Nákupom získate 175 bodov

Anotácia knihy

Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches. A complete characterization of these molecular defects is important for improvement of the strategies for the selection and follow-up of patients undergoing T-cell based cancer immunotherapy. Precise identification of the mechanism leading to MHC class I defects will help to develop new personalized patient-tailored treatment protocols. There is significant new research on the prevalence of various patterns of MHC class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data is available on the changes in MHC class I expression during the course of cancer immunotherapy, but the authors have recently made discoveries that show the progression or regression of a tumor lesion in cancer patients undergoing immunotherapy depends on the molecular mechanism responsible for the MHC class I alteration and not on the type of immunotherapy used. According to this notion, the nature of the preexisting MHC class I lesion in the cancer cell has a crucial impact on determining the final outcome of cancer immunotherapy. This SpringerBrief will present how MHC class 1 is expressed, explain its role in tumor progression, and its role in resistance to immunotherapy.§

Parametre knihy

Zaradenie knihy Knihy po anglicky Medicine Clinical & internal medicine Diseases & disorders

70.78

Obľúbené z iného súdka



Osobný odber Bratislava a 2642 dalších

Copyright ©2008-24 najlacnejsie-knihy.sk Všetky práva vyhradenéSúkromieCookies


Môj účet: Prihlásiť sa
Všetky knihy sveta na jednom mieste. Navyše za skvelé ceny.

Nákupný košík ( prázdny )

Vyzdvihnutie v Zásielkovni
zadarmo nad 59,99 €.

Nachádzate sa: